TABLE 1.
Demographic Characteristics of PACTG 1010 Study Population
| Characteristic | No. of Children |
%of Childrena |
|---|---|---|
| Ageb | ||
| 1 mo to<18 mo | 9 | 9.3 |
| 18 mo to <3 y | 15 | 15.5 |
| 3 y to <8 y | 33 | 34.0 |
| 8 y to <13 y | 40 | 41.2 |
| Gender | ||
| Male | 45 | 46.4 |
| Female | 52 | 53.6 |
| Race/ethnicity | ||
| White, non-Hispanic | 11 | 11.3 |
| Black, non-Hispanic | 59 | 60.8 |
| Hispanic | 26 | 26.8 |
| Other/unknown | 1 | 1.0 |
| CDC clinical stageb | ||
| A, N | 47 | 48.4 |
| B | 32 | 33.0 |
| C | 18 | 18.6 |
| Previous therapyb | ||
| ART naive | 28 | 28.9 |
| PI naive, ART exposed | 23 | 23.7 |
| PI exposed | 46 | 47.4 |
| ART regimen on study | ||
| NRTI | 4 | 4.0 |
| NRTI/NNRTI | 18 | 18.6 |
| NRTI/NNRTI/PI | 19 | 19.6 |
| NRTI/PI | 55 | 56.7 |
| NRTI/NNRTI/FI | 1 | 1.0 |
NRTI indicates nucleoside reverse transcriptase inhibitor; FI, fusion inhibitor (T20).
a
Percentage is of children with known status; percentages may not add to 100 because of rounding.
b
At study entry.